41
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer.

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Population studies have suggested that metformin use in diabetic patients decreases cancer incidence and mortality. Metformin inhibits the growth of cancer cells in vitro and tumors in vivo. However, there is little clinical data to support this. Our purpose was to determine whether metformin use was associated with a change in pathologic complete response (pCR) rates in diabetic patients with breast cancer receiving neoadjuvant chemotherapy.

          Related collections

          Author and article information

          Journal
          J Clin Oncol
          Journal of clinical oncology : official journal of the American Society of Clinical Oncology
          American Society of Clinical Oncology (ASCO)
          1527-7755
          0732-183X
          Jul 10 2009
          : 27
          : 20
          Affiliations
          [1 ] Department of Breast Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, 77030-4009, USA.
          Article
          JCO.2009.19.6410
          10.1200/JCO.2009.19.6410
          2736070
          19487376
          5bd0443f-96b2-469d-923e-e5cbcc249f70
          History

          Comments

          Comment on this article